New Research Examines Long-Term Migraine Prevention as Advances in Targeted Treatments Offer Hope to Millions
New research from South Korea is adding important real-world evidence to the growing field of migraine prevention, examining the safety and effectiveness of fremanezumab, a targeted treatment designed to block a protein involved in migraine attacks. A three-year interim analysis involving more than 1,200 patients found meaningful reductions in monthly migraine days, with over half experiencing at least a 50% improvement after 12 weeks. The findings highlight the potential of targeted therapies while underscoring the need for longer-term patient monitoring.
.webp){kind=spacer}
-v3.jpg)
